Want to see KRRO full AI Analyst Report?
Top Page
Korro Bio
(NASDAQ:KRRO)
Select Model
Select Model
Rating:53Neutral
Price Target:
$13.50
▼(-6.18% Downside)
Action:Reiterated
Date:08/20/26
The score is constrained primarily by weak financial performance—large losses and heavy cash burn that imply ongoing funding risk. Offsetting this, technicals are positive with price strength above major moving averages and supportive momentum, and recent corporate updates show pipeline progress into first-in-human testing. Valuation remains a downside factor because negative earnings make P/E less meaningful and there is no dividend support.
Positive Factors
Clinical Pipeline Advancement
Advancing KRRO-121 from preclinical research toward human testing creates a durable clinical value inflection point and may validate Korro’s RNA-editing approach in rare metabolic disease.
Negative Factors
Persistent Cash Burn
Sustained cash outflows without positive cash generation require continued access to financing and increase the risk that future development will depend on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Pipeline Advancement
Advancing KRRO-121 from preclinical research toward human testing creates a durable clinical value inflection point and may validate Korro’s RNA-editing approach in rare metabolic disease.
Read all positive factors
Korro Bio (KRRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$194.08M
Dividend YieldN/A
Average Volume (3M)262.13K
Price to Earnings (P/E)―
Beta (1Y)2.81
Revenue Growth-62.08%
EPS Growth-2.62%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.01
Shares Outstanding14,725,646
10 Day Avg. Volume177,891
30 Day Avg. Volume262,130
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.71Price Target Upside30.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$562.50K
Korro Bio Business Overview & Revenue Model
Company Description
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wid...
How the Company Makes Money
null...
Korro Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.38M | 6.39M | 2.27M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.73M | 2.11M | 2.27M | 0.00 | 0.00 | 0.00 |
| EBITDA | -71.92M | -83.06M | -88.34M | -80.90M | -56.49M | -33.90M |
| Net Income | -106.64M | -117.26M | -83.58M | -81.17M | -58.03M | -21.96M |
Balance Sheet | ||||||
| Total Assets | 163.45M | 113.51M | 226.24M | 221.66M | 73.74M | 185.36M |
| Cash, Cash Equivalents and Short-Term Investments | 115.04M | 75.16M | 126.09M | 166.15M | 55.85M | 130.71M |
| Total Debt | 42.21M | 43.49M | 44.77M | 33.21M | 166.99M | 45.60M |
| Total Liabilities | 60.22M | 62.07M | 65.83M | 51.75M | 172.77M | 54.53M |
| Stockholders Equity | 103.23M | 51.44M | 160.41M | 169.91M | -99.03M | 130.82M |
Cash Flow | ||||||
| Free Cash Flow | -68.27M | -79.08M | -77.98M | -75.12M | -58.86M | -36.54M |
| Operating Cash Flow | -67.95M | -78.56M | -60.07M | -67.28M | -53.65M | -32.09M |
| Investing Cash Flow | -27.63M | 43.99M | -123.35M | 11.16M | 11.06M | -39.50M |
| Financing Cash Flow | 85.80M | 685.00K | 69.36M | 187.76M | 18.00K | 115.94M |
Korro Bio Technical Analysis
Positive
14.39
Price Trends
12.54
Positive
12.47
Positive
11.85
Positive
Market Momentum
0.35
Negative
55.68
Neutral
48.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Positive. The current price of 14.39 is above the 20-day moving average (MA) of 12.21, above the 50-day MA of 12.54, and above the 200-day MA of 11.85, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 55.68 is Neutral, neither overbought nor oversold. The STOCH value of 48.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRRO.
Korro Bio Risk Analysis
Korro Bio disclosed 85 risk factors in its most recent earnings report. Korro Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Korro Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $700.00M | 64.15 | -0.02% | ― | 125.12% | 98.69% | |
59 Neutral | $961.17M | -4.36 | -106.15% | ― | ― | 10.96% | |
56 Neutral | $874.52M | -5.66 | -41.33% | ― | 278712.12% | 26.59% | |
53 Neutral | $194.08M | -1.31 | -114.26% | ― | -62.08% | -2.62% | |
52 Neutral | $938.10M | -12.91 | -34.03% | ― | ― | -5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
39 Underperform | $808.90M | -4.44 | -73.18% | ― | ― | 9.05% |
* Healthcare Sector Average
KRRO
Korro Bio
13.07
-7.00
-34.88%
ASMB
Assembly Biosciences
35.28
8.66
32.53%
ANNX
Annexon Biosciences
5.06
2.91
135.35%
FDMT
4D Molecular Therapeutics
15.39
8.65
128.34%
DSGN
Design Therapeutics
15.23
10.03
192.88%
AURA
Aura Biosciences Inc
7.90
1.38
21.17%
Korro Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Korro Bio Advances KRRO-121 Into First Human Trial
Positive
Aug 19, 2026
On August 19, 2026, Korro Bio, Inc. reported it had submitted an application to the Australian Alfred Health Human Ethics Committee to begin a first-in-human Phase 1/2 clinical trial of KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide for...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Korro Bio Refines Capital Structure with Exchange Agreement
Positive
Aug 6, 2026
On August 5, 2026, Korro Bio entered into an exchange agreement with Venrock Healthcare Capital Partners in which Venrock surrendered 1,000,000 Korro common shares for no consideration in exchange for pre-funded warrants to purchase the same numbe...
Executive/Board ChangesShareholder Meetings
Korro Bio Stockholders Approve Directors, Pay and Auditor
Positive
Jun 11, 2026
At its annual meeting of stockholders held on June 10, 2026, Korro Bio, Inc. reported that shareholders elected Nessan Bermingham and Rachel Meyers as Class I directors to three-year terms ending in 2029. The vote results showed strong support for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.